詳細検索

詳細検索

お問い合わせ

Global Cattle and Sheep Vaccine Market Outlook, InDepth Analysis & Forecast to 2032

Global Cattle and Sheep Vaccine Market Outlook, InDepth Analysis & Forecast to 2032


家畜(牛・羊)用ワクチンの世界市場 2026-2032年

The global Cattle and Sheep Vaccine market is projected to grow from US$ 2447 million in 2025 to US$ 3610 million by 2032, at a CAGR of 6.1% (2026-2032), driven by critical product segments and div... もっと見る

 

 

出版社
QYResearch
QYリサーチ
出版年月
2026年11月15日
電子版価格
US$4,900
シングルユーザライセンス
ライセンス・価格情報/注文方法はこちら
納期
5-7営業日
言語
英語

英語原文をAIを使って翻訳しています。


 

お問い合わせ

お問合せ種類/内容 *

補足が有ればご記入ください
貴社名*
ご担当者名 * 姓 名
メールアドレス *

ページTOPに戻る



図表リスト

List of Tables
Table 1. Global Cattle and Sheep Vaccine Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Table 2. Global Cattle and Sheep Vaccine Market Size Growth Rate by Preventing Disease, 2021 vs 2025 vs 2032 (US$ Million)
Table 3. Global Cattle and Sheep Vaccine Market Size Growth Rate by Antigen Combination, 2021 vs 2025 vs 2032 (US$ Million)
Table 4. Global Cattle and Sheep Vaccine Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Table 5. Global Cattle and Sheep Vaccine Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 6. Global Cattle and Sheep Vaccine Revenue by Region (US$ Million), 2021-2026
Table 7. Global Cattle and Sheep Vaccine Revenue by Region (US$ Million), 2027-2032
Table 8. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 9. Global Cattle and Sheep Vaccine Revenue by Players (US$ Million), 2021-2026
Table 10. Global Cattle and Sheep Vaccine Revenue-Based Market Share by Players (2021-2026)
Table 11. Global Key Players’Ranking Shift (2024 vs 2025) (Based on Revenue)
Table 12. Global Companies by Tier (Tier 1, Tier 2, and Tier 3), based on Cattle and Sheep Vaccine Revenue, 2025
Table 13. Global Cattle and Sheep Vaccine Average Gross Margin (%) by Player (2021 vs 2025)
Table 14. Global Cattle and Sheep Vaccine Companies Headquarters
Table 15. Global Cattle and Sheep Vaccine Market Concentration Ratio (CR5)
Table 16. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis
Table 17. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 18. Global Cattle and Sheep Vaccine Revenue by Type (US$ Million), 2021-2026
Table 19. Global Cattle and Sheep Vaccine Revenue by Type (US$ Million), 2027-2032
Table 20. Global Cattle and Sheep Vaccine Revenue by Preventing Disease (US$ Million), 2021-2026
Table 21. Global Cattle and Sheep Vaccine Revenue by Preventing Disease (US$ Million), 2027-2032
Table 22. Global Cattle and Sheep Vaccine Revenue by Antigen Combination (US$ Million), 2021-2026
Table 23. Global Cattle and Sheep Vaccine Revenue by Antigen Combination (US$ Million), 2027-2032
Table 24. Key Product Attributes and Differentiation
Table 25. Global Cattle and Sheep Vaccine Revenue by Application (US$ Million), 2021-2026
Table 26. Global Cattle and Sheep Vaccine Revenue by Application (US$ Million), 2027-2032
Table 27. Cattle and Sheep Vaccine High-Growth Sectors Demand CAGR (2026-2032)
Table 28. Top Customers by Region
Table 29. Top Customers by Application
Table 30. North America Cattle and Sheep Vaccine Growth Accelerators and Market Barriers
Table 31. North America Cattle and Sheep Vaccine Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 32. Europe Cattle and Sheep Vaccine Growth Accelerators and Market Barriers
Table 33. Europe Cattle and Sheep Vaccine Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 34. Asia-Pacific Cattle and Sheep Vaccine Growth Accelerators and Market Barriers
Table 35. Asia-Pacific Cattle and Sheep Vaccine Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Central and South America Cattle and Sheep Vaccine Investment Opportunities and Key Challenges
Table 37. Central and South America Cattle and Sheep Vaccine Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 38. Middle East and Africa Cattle and Sheep Vaccine Investment Opportunities and Key Challenges
Table 39. Middle East and Africa Cattle and Sheep Vaccine Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 40. MSD Animal Health(Merck) Corporation Information
Table 41. MSD Animal Health(Merck) Description and Major Businesses
Table 42. MSD Animal Health(Merck) Product Features and Attributes
Table 43. MSD Animal Health(Merck) Revenue (US$ Million) and Gross Margin (2021-2026)
Table 44. MSD Animal Health(Merck) Revenue Proportion by Product in 2025
Table 45. MSD Animal Health(Merck) Revenue Proportion by Application in 2025
Table 46. MSD Animal Health(Merck) Revenue Proportion by Geographic Area in 2025
Table 47. MSD Animal Health(Merck) Cattle and Sheep Vaccine SWOT Analysis
Table 48. MSD Animal Health(Merck) Recent Developments
Table 49. Zoetis Corporation Information
Table 50. Zoetis Description and Major Businesses
Table 51. Zoetis Product Features and Attributes
Table 52. Zoetis Revenue (US$ Million) and Gross Margin (2021-2026)
Table 53. Zoetis Revenue Proportion by Product in 2025
Table 54. Zoetis Revenue Proportion by Application in 2025
Table 55. Zoetis Revenue Proportion by Geographic Area in 2025
Table 56. Zoetis Cattle and Sheep Vaccine SWOT Analysis
Table 57. Zoetis Recent Developments
Table 58. Boehringer Ingelheim Corporation Information
Table 59. Boehringer Ingelheim Description and Major Businesses
Table 60. Boehringer Ingelheim Product Features and Attributes
Table 61. Boehringer Ingelheim Revenue (US$ Million) and Gross Margin (2021-2026)
Table 62. Boehringer Ingelheim Revenue Proportion by Product in 2025
Table 63. Boehringer Ingelheim Revenue Proportion by Application in 2025
Table 64. Boehringer Ingelheim Revenue Proportion by Geographic Area in 2025
Table 65. Boehringer Ingelheim Cattle and Sheep Vaccine SWOT Analysis
Table 66. Boehringer Ingelheim Recent Developments
Table 67. Ceva Santé Animale Corporation Information
Table 68. Ceva Santé Animale Description and Major Businesses
Table 69. Ceva Santé Animale Product Features and Attributes
Table 70. Ceva Santé Animale Revenue (US$ Million) and Gross Margin (2021-2026)
Table 71. Ceva Santé Animale Revenue Proportion by Product in 2025
Table 72. Ceva Santé Animale Revenue Proportion by Application in 2025
Table 73. Ceva Santé Animale Revenue Proportion by Geographic Area in 2025
Table 74. Ceva Santé Animale Cattle and Sheep Vaccine SWOT Analysis
Table 75. Ceva Santé Animale Recent Developments
Table 76. Elanco Animal Health Corporation Information
Table 77. Elanco Animal Health Description and Major Businesses
Table 78. Elanco Animal Health Product Features and Attributes
Table 79. Elanco Animal Health Revenue (US$ Million) and Gross Margin (2021-2026)
Table 80. Elanco Animal Health Revenue Proportion by Product in 2025
Table 81. Elanco Animal Health Revenue Proportion by Application in 2025
Table 82. Elanco Animal Health Revenue Proportion by Geographic Area in 2025
Table 83. Elanco Animal Health Cattle and Sheep Vaccine SWOT Analysis
Table 84. Elanco Animal Health Recent Developments
Table 85. Indian Immunologicals Limited Corporation Information
Table 86. Indian Immunologicals Limited Description and Major Businesses
Table 87. Indian Immunologicals Limited Product Features and Attributes
Table 88. Indian Immunologicals Limited Revenue (US$ Million) and Gross Margin (2021-2026)
Table 89. Indian Immunologicals Limited Recent Developments
Table 90. Cambridge Technologies Corporation Information
Table 91. Cambridge Technologies Description and Major Businesses
Table 92. Cambridge Technologies Product Features and Attributes
Table 93. Cambridge Technologies Revenue (US$ Million) and Gross Margin (2021-2026)
Table 94. Cambridge Technologies Recent Developments
Table 95. Bioveta Corporation Information
Table 96. Bioveta Description and Major Businesses
Table 97. Bioveta Product Features and Attributes
Table 98. Bioveta Revenue (US$ Million) and Gross Margin (2021-2026)
Table 99. Bioveta Recent Developments
Table 100. Virbac Corporation Information
Table 101. Virbac Description and Major Businesses
Table 102. Virbac Product Features and Attributes
Table 103. Virbac Revenue (US$ Million) and Gross Margin (2021-2026)
Table 104. Virbac Recent Developments
Table 105. CZ Vaccines(Zendal Group) Corporation Information
Table 106. CZ Vaccines(Zendal Group) Description and Major Businesses
Table 107. CZ Vaccines(Zendal Group) Product Features and Attributes
Table 108. CZ Vaccines(Zendal Group) Revenue (US$ Million) and Gross Margin (2021-2026)
Table 109. CZ Vaccines(Zendal Group) Recent Developments
Table 110. Vaxxinova Corporation Information
Table 111. Vaxxinova Description and Major Businesses
Table 112. Vaxxinova Product Features and Attributes
Table 113. Vaxxinova Revenue (US$ Million) and Gross Margin (2021-2026)
Table 114. Vaxxinova Recent Developments
Table 115. Hester Biosciences Corporation Information
Table 116. Hester Biosciences Description and Major Businesses
Table 117. Hester Biosciences Product Features and Attributes
Table 118. Hester Biosciences Revenue (US$ Million) and Gross Margin (2021-2026)
Table 119. Hester Biosciences Recent Developments
Table 120. Jinyu Bio-Technology Corporation Information
Table 121. Jinyu Bio-Technology Description and Major Businesses
Table 122. Jinyu Bio-Technology Product Features and Attributes
Table 123. Jinyu Bio-Technology Revenue (US$ Million) and Gross Margin (2021-2026)
Table 124. Jinyu Bio-Technology Recent Developments
Table 125. CAHIC Corporation Information
Table 126. CAHIC Description and Major Businesses
Table 127. CAHIC Product Features and Attributes
Table 128. CAHIC Revenue (US$ Million) and Gross Margin (2021-2026)
Table 129. CAHIC Recent Developments
Table 130. TECON Biology Corporation Information
Table 131. TECON Biology Description and Major Businesses
Table 132. TECON Biology Product Features and Attributes
Table 133. TECON Biology Revenue (US$ Million) and Gross Margin (2021-2026)
Table 134. TECON Biology Recent Developments
Table 135. Harbin Pharmaceutical Group Corporation Information
Table 136. Harbin Pharmaceutical Group Description and Major Businesses
Table 137. Harbin Pharmaceutical Group Product Features and Attributes
Table 138. Harbin Pharmaceutical Group Revenue (US$ Million) and Gross Margin (2021-2026)
Table 139. Harbin Pharmaceutical Group Recent Developments
Table 140. China Agricultural Vet Biology and Technology Co., LTD Corporation Information
Table 141. China Agricultural Vet Biology and Technology Co., LTD Description and Major Businesses
Table 142. China Agricultural Vet Biology and Technology Co., LTD Product Features and Attributes
Table 143. China Agricultural Vet Biology and Technology Co., LTD Revenue (US$ Million) and Gross Margin (2021-2026)
Table 144. China Agricultural Vet Biology and Technology Co., LTD Recent Developments
Table 145. HIPRA Corporation Information
Table 146. HIPRA Description and Major Businesses
Table 147. HIPRA Product Features and Attributes
Table 148. HIPRA Revenue (US$ Million) and Gross Margin (2021-2026)
Table 149. HIPRA Recent Developments
Table 150. Syva Corporation Information
Table 151. Syva Description and Major Businesses
Table 152. Syva Product Features and Attributes
Table 153. Syva Revenue (US$ Million) and Gross Margin (2021-2026)
Table 154. Syva Recent Developments
Table 155. Pulike Corporation Information
Table 156. Pulike Description and Major Businesses
Table 157. Pulike Product Features and Attributes
Table 158. Pulike Revenue (US$ Million) and Gross Margin (2021-2026)
Table 159. Pulike Recent Developments
Table 160. Shenlian Biomedical Corporation Information
Table 161. Shenlian Biomedical Description and Major Businesses
Table 162. Shenlian Biomedical Product Features and Attributes
Table 163. Shenlian Biomedical Revenue (US$ Million) and Gross Margin (2021-2026)
Table 164. Shenlian Biomedical Recent Developments
Table 165. INNER MONGOLIA BIGVETBIOTECH Corporation Information
Table 166. INNER MONGOLIA BIGVETBIOTECH Description and Major Businesses
Table 167. INNER MONGOLIA BIGVETBIOTECH Product Features and Attributes
Table 168. INNER MONGOLIA BIGVETBIOTECH Revenue (US$ Million) and Gross Margin (2021-2026)
Table 169. INNER MONGOLIA BIGVETBIOTECH Recent Developments
Table 170. Sinopharm Animal Health Corporation Information
Table 171. Sinopharm Animal Health Description and Major Businesses
Table 172. Sinopharm Animal Health Product Features and Attributes
Table 173. Sinopharm Animal Health Revenue (US$ Million) and Gross Margin (2021-2026)
Table 174. Sinopharm Animal Health Recent Developments
Table 175. HVRI Corporation Information
Table 176. HVRI Description and Major Businesses
Table 177. HVRI Product Features and Attributes
Table 178. HVRI Revenue (US$ Million) and Gross Margin (2021-2026)
Table 179. HVRI Recent Developments
Table 180. Jilin Zhengye Corporation Information
Table 181. Jilin Zhengye Description and Major Businesses
Table 182. Jilin Zhengye Product Features and Attributes
Table 183. Jilin Zhengye Revenue (US$ Million) and Gross Margin (2021-2026)
Table 184. Jilin Zhengye Recent Developments
Table 185. Technologies, Platforms and Infrastructure
Table 186. Distributors List
Table 187. Market Trends and Market Evolution
Table 188. Market Drivers and Opportunities
Table 189. Market Challenges, Risks, and Restraints
Table 190. Research Programs/Design for This Report
Table 191. Key Data Information from Secondary Sources
Table 192. Key Data Information from Primary Sources

List of Figures
Figure 1. Global Cattle and Sheep Vaccine Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Figure 2. Live Attenuated Vaccine Product Picture
Figure 3. Inactivated Vaccine Product Picture
Figure 4. Others Product Picture
Figure 5. Global Cattle and Sheep Vaccine Market Size Growth Rate by Preventing Disease, 2021 vs 2025 vs 2032 (US$ Million)
Figure 6. Foot-and-Mouth Disease Vaccines Product Picture
Figure 7. Bovine Respiratory Disease Vaccines Product Picture
Figure 8. Clostridial Vaccines Product Picture
Figure 9. Others Product Picture
Figure 10. Global Cattle and Sheep Vaccine Market Size Growth Rate by Antigen Combination, 2021 vs 2025 vs 2032 (US$ Million)
Figure 11. Monovalent Live Vaccines Product Picture
Figure 12. Bivalent Live Vaccines Product Picture
Figure 13. Multivalent Live Vaccines Product Picture
Figure 14. Global Cattle and Sheep Vaccine Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Figure 15. Cattle Farming
Figure 16. Sheep Farming
Figure 17. Others
Figure 18. Cattle and Sheep Vaccine Report Years Considered
Figure 19. Global Cattle and Sheep Vaccine Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 20. Global Cattle and Sheep Vaccine Revenue (US$ Million), 2021-2032
Figure 21. Global Cattle and Sheep Vaccine Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Figure 22. Global Cattle and Sheep Vaccine Revenue-Based Market Share by Region (2021-2032)
Figure 23. Global Cattle and Sheep Vaccine Revenue-Based Market Share Ranking (2025)
Figure 24. Tier Distribution by Revenue Contribution (2021 vs 2025)
Figure 25. Live Attenuated Vaccine Revenue-Based Market Share by Player in 2025
Figure 26. Inactivated Vaccine Revenue-Based Market Share by Player in 2025
Figure 27. Others Revenue-Based Market Share by Player in 2025
Figure 28. Global Cattle and Sheep Vaccine Revenue-Based Market Share by Type (2021-2032)
Figure 29. Global Cattle and Sheep Vaccine Revenue-Based Market Share by Preventing Disease (2021-2032)
Figure 30. Global Cattle and Sheep Vaccine Revenue-Based Market Share by Antigen Combination (2021-2032)
Figure 31. Global Cattle and Sheep Vaccine Revenue-Based Market Share by Application (2021-2032)
Figure 32. North America Cattle and Sheep Vaccine Revenue YoY (US$ Million), 2021-2032
Figure 33. North America Top 5 Players Cattle and Sheep Vaccine Revenue (US$ Million) in 2025
Figure 34. North America Cattle and Sheep Vaccine Revenue (US$ Million) by Application (2021-2032)
Figure 35. US Cattle and Sheep Vaccine Revenue (US$ Million), 2021-2032
Figure 36. Canada Cattle and Sheep Vaccine Revenue (US$ Million), 2021-2032
Figure 37. Mexico Cattle and Sheep Vaccine Revenue (US$ Million), 2021-2032
Figure 38. Europe Cattle and Sheep Vaccine Revenue YoY (US$ Million), 2021-2032
Figure 39. Europe Top 5 Players Cattle and Sheep Vaccine Revenue (US$ Million) in 2025
Figure 40. Europe Cattle and Sheep Vaccine Revenue (US$ Million) by Application (2021-2032)
Figure 41. Germany Cattle and Sheep Vaccine Revenue (US$ Million), 2021-2032
Figure 42. France Cattle and Sheep Vaccine Revenue (US$ Million), 2021-2032
Figure 43. U.K. Cattle and Sheep Vaccine Revenue (US$ Million), 2021-2032
Figure 44. Italy Cattle and Sheep Vaccine Revenue (US$ Million), 2021-2032
Figure 45. Russia Cattle and Sheep Vaccine Revenue (US$ Million), 2021-2032
Figure 46. Asia-Pacific Cattle and Sheep Vaccine Revenue YoY (US$ Million), 2021-2032
Figure 47. Asia-Pacific Top 8 Players Cattle and Sheep Vaccine Revenue (US$ Million) in 2025
Figure 48. Asia-Pacific Cattle and Sheep Vaccine Revenue (US$ Million) by Application (2021-2032)
Figure 49. Indonesia Cattle and Sheep Vaccine Revenue (US$ Million), 2021-2032
Figure 50. Japan Cattle and Sheep Vaccine Revenue (US$ Million), 2021-2032
Figure 51. South Korea Cattle and Sheep Vaccine Revenue (US$ Million), 2021-2032
Figure 52. Australia Cattle and Sheep Vaccine Revenue (US$ Million), 2021-2032
Figure 53. India Cattle and Sheep Vaccine Revenue (US$ Million), 2021-2032
Figure 54. Indonesia Cattle and Sheep Vaccine Revenue (US$ Million), 2021-2032
Figure 55. Vietnam Cattle and Sheep Vaccine Revenue (US$ Million), 2021-2032
Figure 56. Malaysia Cattle and Sheep Vaccine Revenue (US$ Million), 2021-2032
Figure 57. Philippines Cattle and Sheep Vaccine Revenue (US$ Million), 2021-2032
Figure 58. Singapore Cattle and Sheep Vaccine Revenue (US$ Million), 2021-2032
Figure 59. Central and South America Cattle and Sheep Vaccine Revenue YoY (US$ Million), 2021-2032
Figure 60. Central and South America Top 5 Players Cattle and Sheep Vaccine Revenue (US$ Million) in 2025
Figure 61. Central and South America Cattle and Sheep Vaccine Revenue (US$ Million) by Application (2021-2032)
Figure 62. Brazil Cattle and Sheep Vaccine Revenue (US$ Million), 2021-2032
Figure 63. Argentina Cattle and Sheep Vaccine Revenue (US$ Million), 2021-2032
Figure 64. Middle East and Africa Cattle and Sheep Vaccine Revenue YoY (US$ Million), 2021-2032
Figure 65. Middle East and Africa Top 5 Players Cattle and Sheep Vaccine Revenue (US$ Million) in 2025
Figure 66. Middle East and Africa Cattle and Sheep Vaccine Revenue (US$ Million) by Application (2021-2032)
Figure 67. GCC Countries Cattle and Sheep Vaccine Revenue (US$ Million), 2021-2032
Figure 68. Israel Cattle and Sheep Vaccine Revenue (US$ Million), 2021-2032
Figure 69. Egypt Cattle and Sheep Vaccine Revenue (US$ Million), 2021-2032
Figure 70. South Africa Cattle and Sheep Vaccine Revenue (US$ Million), 2021-2032
Figure 71. Cattle and Sheep Vaccine Value Chain Mapping
Figure 72. Channels of Distribution (Direct Vs Distribution)
Figure 73. Bottom-up and Top-down Approaches for This Report
Figure 74. Data Triangulation
Figure 75. Key Executives Interviewed

 

ページTOPに戻る


 

Summary

The global Cattle and Sheep Vaccine market is projected to grow from US$ 2447 million in 2025 to US$ 3610 million by 2032, at a CAGR of 6.1% (2026-2032), driven by critical product segments and diverse end‑use applications.

Cattle and Sheep Vaccine refers to veterinary biological products used for active immunization and herd-level prevention of infectious diseases in cattle, sheep, and other ruminants. The products introduce live attenuated pathogens, inactivated pathogens, bacterial toxoids, recombinant antigens, or other immunogenic components to stimulate specific humoral, cellular, or mucosal immunity. By vaccine type, the product is divided into Live Attenuated Vaccines, Inactivated Vaccines, and Others; by Preventing Disease, into Foot-and-Mouth Disease Vaccines, Bovine Respiratory Disease Vaccines, Clostridial Vaccines, and Others; and by Antigen Combination, into Monovalent Live Vaccines, Bivalent Live Vaccines, and Multivalent Live Vaccines. Major formulations include lyophilized live vaccines, liquid inactivated vaccines, oil-emulsion formulations, aluminum-adjuvanted vaccines, and bacterial toxoids, administered mainly by subcutaneous, intramuscular, or intranasal routes.

Key Findings
The average industry gross margin of the product in 2025 is approximately 40%–60%.

Inactivated Vaccines are estimated to represent the largest value segment, with standard commercial Foot-and-Mouth Disease vaccines providing ≥3 PD50 per dose.

Cattle Farming represents the largest downstream application.

Zoetis, MSD Animal Health, Boehringer Ingelheim, Ceva Santé Animale, and Elanco Animal Health are positioned among the leading global suppliers.

Market Trends
The product is evolving from traditional monovalent and single-disease vaccination toward multivalent combinations, highly purified antigens, advanced adjuvants, DIVA differentiation, and precision immunization. Foot-and-Mouth Disease remains centered on inactivated technology because WOAH does not accept live FMD vaccines due to reversion-to-virulence risks, making high potency, multiserotype matching, and NSP purification important technology directions. Ceva's Aftomune uses bivalent O1 Campos and A24 Cruzeiro inactivated antigens and removes non-structural proteins to support differentiation of infected from vaccinated animals. Bovine Respiratory Disease products continue to move toward combinations of IBR, BVD, PI3, BRSV, and bacterial antigens, with selected Elanco products providing coverage against up to 11 respiratory and reproductive antigens. Future development will emphasize fewer injections, longer protection, and digital herd-vaccination management.

Market Dynamics
Drivers
Demand for the product is mainly driven by large-scale cattle and sheep farming, prevention of major livestock diseases such as Foot-and-Mouth Disease, control of respiratory disease in calves, and prevention of clostridial disease in lambs. FMD control in endemic regions requires high population immunity, and WOAH recommends vaccination coverage of at least 80% of the target population together with good antigenic matching between vaccine and circulating field strains. Bovine Respiratory Disease is a major health challenge in beef and dairy calves, making multivalent respiratory vaccination an important component of preconditioning, weaning, and feedlot-arrival programs. Sheep production also relies heavily on Clostridium perfringens and tetanus toxoid vaccines to reduce lamb mortality and production losses.

Restraints
The main restraints include dependence on cold-chain management, complex vaccination schedules, regional differences in disease epidemiology, and restrictions on selected live vaccines during pregnancy. Live Attenuated Vaccines can generate strong immunity, but certain IBR- and BVD-containing live products have specific safety restrictions in pregnant cattle that have not been appropriately primed, making strict label-based vaccination programs necessary. Inactivated Vaccines usually have broader safety margins, but because the antigen cannot replicate, they commonly require a two-dose primary course followed by periodic boosters. FMD vaccines additionally require continuing strain matching because reliable cross-protection does not exist across all serotypes. Cold-chain interruption, freezing of oil-emulsion products, or incorrect field dosage can also reduce protection.

Opportunities
Future opportunities are concentrated in Multivalent Vaccines, DIVA-compatible products, advanced respiratory combinations, regional FMD antigen banks, and vaccines for emerging diseases. Multivalent inactivated FMD products can cover several circulating serotypes in one vaccination; standard commercial vaccines generally provide at least 3 PD50 per dose, while high-potency emergency products may provide ≥6 PD50 per dose. In Bovine Respiratory Disease, combinations have expanded beyond conventional four- or five-way products toward portfolios covering more than ten viral, bacterial, and reproductive antigens. Recent European BTV-3 outbreaks have also created additional demand within the Others category, and Boehringer Ingelheim has introduced an inactivated BTV-3 vaccine for cattle and sheep. Low-volume, high-purity, long-duration, and broad-combination products are likely to capture higher value.

Challenges
The core challenges are cross-protection, antigenic matching, long-term safety, and batch consistency. Foot-and-Mouth Disease virus contains multiple serotypes and numerous antigenic variants, and inadequate matching between vaccine and field strains can substantially reduce real-world protection, requiring continued antigenic matching and reference-laboratory surveillance. Bovine Respiratory Disease is also multifactorial, involving viruses, bacteria, stress, and environmental conditions, so vaccination cannot replace ventilation, nutrition, and biosecurity management. Multivalent products reduce administration frequency but can create antigen-interference challenges, requiring careful optimization of adjuvants, antigen doses, and timing. In sheep, maternal vaccination against clostridial disease must also be synchronized with pregnancy to maximize colostral antibody transfer to lambs.

Industry Chain Analysis
The upstream supply chain mainly includes master and working seed strains, BHK and other cell lines, cell-culture media, bacterial fermentation substrates, production equipment, inactivating agents, adjuvants, stabilizers, lyophilization protectants, glass vials, and cold-chain packaging. Seed purity, cell-substrate safety, antigen concentration, and adjuvant performance directly influence final product quality. Midstream activities include virus or bacterial propagation, antigen harvesting, concentration and purification, attenuation or inactivation, toxoid preparation, antigen quantification, adjuvant emulsification, aseptic filling, potency and safety testing, and batch release. Ceva Aftomune, for example, uses FMD virus propagated in BHK21 cells, followed by BEI inactivation, purification, concentration, and water-in-oil emulsification. Downstream demand comes from Cattle Farming, Sheep Farming, and Other ruminant operations through veterinary distributors, integrated farms, government disease-control procurement, and veterinary service channels, supported by cold-chain distribution, serological monitoring, vaccination-program design, and herd-health management.

Segment Insights
By vaccine type and Preventing Disease, Inactivated Vaccines are estimated to represent the largest value segment, with Foot-and-Mouth Disease being one of the most important high-volume applications. WOAH specifies at least 3 PD50 per dose for standard commercial FMD vaccines and ≥6 PD50 for high-potency emergency vaccines, and only inactivated virus vaccines are acceptable. Ceva's bivalent Aftomune contains O1 Campos and A24 Cruzeiro antigens and is administered to cattle at 2 mL by the intramuscular or subcutaneous route. Bovine Respiratory Disease includes both Live Attenuated, Inactivated, and mixed-antigen products. BOVILIS VISTA 5 SQ covers IBR, BVD Types 1 and 2, BRSV, and PI3 at a 2 mL subcutaneous dose, with selected viral components demonstrating approximately one year of immunity.

By Antigen Combination, Monovalent Live Vaccines are suited to targeted protection against a single pathogen or regional disease challenge; Bivalent Live Vaccines reduce handling where two pathogens or strains need simultaneous coverage; and Multivalent Live Vaccines provide higher value in modern respiratory and reproductive disease programs. The commercial market also contains extensive multivalent inactivated products. Clostridial vaccines can cover seven to nine antigens in one injection: Merck's Cavalry 9 protects against nine clostridial disease components, including tetanus, blackleg, and enterotoxemia, with a typical 2 mL dose, while cattle-and-sheep CD-T products commonly use a 2 mL subcutaneous dose. Technology is shifting from simple single-antigen formulations toward broader combinations, advanced adjuvants, and fewer injections.

Downstream Market Opportunities
Cattle Farming represents the largest end-use market. Beef calves and feedlot cattle emphasize prevention of BRD, Clostridial Disease, and FMD, while dairy cattle additionally require vaccination programs for reproductive disease, mastitis, and calf enteric disease. Sheep Farming is strongly focused on clostridial disease, tetanus, bluetongue, and FMD, while vaccination of pregnant ewes is used to increase colostral antibody protection for newborn lambs. Selected respiratory vaccines can be administered to cattle from approximately three months of age at 2 mL, while common cattle-and-sheep clostridial products may use approximately 1 mL for sheep and 2 mL for cattle. Artificial intelligence is not part of the vaccine itself, but ear-tag data, body temperature, feed intake, cough monitoring, reproductive records, and regional outbreak information can be integrated to predict high-risk groups and optimize vaccination timing, booster intervals, and disease combinations, supporting a transition from fixed schedules toward risk-based immunization.

Regional Insights
North America is a high-value market for Bovine Respiratory Disease, multivalent Clostridial, and reproductive vaccines, with Zoetis, MSD Animal Health, Boehringer Ingelheim, and Elanco maintaining broad cattle vaccine portfolios; routine FMD vaccination is limited because countries such as the United States maintain FMD-free status. Europe has a mature regulatory system for cattle and sheep vaccines, and regional diseases such as bluetongue continue to generate demand for new products alongside respiratory and clostridial vaccines. Parts of Asia, Africa, and South America continue to conduct FMD vaccination programs, where government procurement and mass immunization play important roles; WOAH emphasizes high population coverage and vaccine matching in such programs. China and India also have large cattle and sheep populations and local vaccine manufacturing industries, with Jinyu Bio-Technology, CAHIC, TECON Biology, Pulike, Shenlian Biomedical, and Sinopharm Animal Health participating in regional competition.

Competitive Landscape Analysis
The product market has substantial barriers in biological manufacturing facilities, seed-strain resources, cell-culture technology, regulatory approval, and cold-chain services. Representative leading players include Zoetis, MSD Animal Health (Merck), Boehringer Ingelheim, Ceva Santé Animale, and Elanco Animal Health. Zoetis maintains broad respiratory and reproductive portfolios through PregGuard, CattleMaster, and related multivalent vaccines. MSD uses the BOVILIS/VISTA and VISION families to cover Bovine Respiratory Disease and Clostridial Disease and also maintains sheep-health vaccine solutions. Boehringer Ingelheim offers PYRAMID, EXPRESS, TRIANGLE, and Bluetongue products. Ceva has a strong position in inactivated FMD through Aftomune and uses NSP purification to support DIVA strategies. Elanco combines Live Attenuated, Inactivated, and combination respiratory products through Titanium, NUPLURA, and Vira Shield. Competitive differentiation has expanded from basic antigen supply toward multivalent coverage, duration of protection, low vaccine reactivity, DIVA capability, farm support, and digital disease-management services.

Report Scope
This definitive report equips business leaders, decision-makers, and stakeholders with a 360° view of the global Cattle and Sheep Vaccine market across value chain. It analyzes historical revenue data (2021–2025) and delivers forecasts through 2032, illuminating demand trends and growth drivers.

By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customer distribution pattern.

Granular regional insights cover five major markets (North America, Europe, APAC, South America, and MEA) with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.

Critical competitive intelligence profiles players (revenue, margins, pricing strategies, and major customers) and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.

A concise Industry‑chain overview maps upstream, middle stream, and downstream distribution dynamics to identify strategic gaps and unmet demand.

Market Segmentation
By Company
MSD Animal Health(Merck)
Zoetis
Boehringer Ingelheim
Ceva Santé Animale
Elanco Animal Health
Indian Immunologicals Limited
Cambridge Technologies
Bioveta
Virbac
CZ Vaccines(Zendal Group)
Vaxxinova
Hester Biosciences
Jinyu Bio-Technology
CAHIC
TECON Biology
Harbin Pharmaceutical Group
China Agricultural Vet Biology and Technology Co., LTD
HIPRA
Syva
Pulike
Shenlian Biomedical
INNER MONGOLIA BIGVETBIOTECH
Sinopharm Animal Health
HVRI
Jilin Zhengye

Segment by Type
Live Attenuated Vaccine
Inactivated Vaccine
Others

Segment by Preventing Disease
Foot-and-Mouth Disease Vaccines
Bovine Respiratory Disease Vaccines
Clostridial Vaccines
Others

Segment by Antigen Combination
Monovalent Live Vaccines
Bivalent Live Vaccines
Multivalent Live Vaccines

Segment by Application
Cattle Farming
Sheep Farming
Others

Segment by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of Central and South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA

Chapter Outline
Chapter 1: Defines the Cattle and Sheep Vaccine study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential
Chapter 2: Offers current market state, projects global revenue and sales to 2032, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape: ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves
Chapter 4: Unlocks high margin product segments: compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities: evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application
Chapter 6: North America: breaks down market size by Application and country, profiles key players and assesses growth drivers and barriers
Chapter 7: Europe: analyses regional market by Application and players, flagging drivers and barriers
Chapter 8: Asia Pacific: quantifies market size by Application, and region/country, profiles top players, and uncovers high potential expansion areas
Chapter 9: Central & South America: measures market size by Application, and country, profiles top players, and identifies investment opportunities and challenges
Chapter 10: Middle East and Africa: evaluates market size by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth: details product specs, revenue, margins; top-tier players 2025 sales breakdowns by product type, by Application, by region SWOT analysis, and recent strategic developments
Chapter 12: Value chain and ecosystem: analyses upstream, midstream, plus downstream channels
Chapter 13: Market dynamics: explores drivers, restraints, regulatory impacts, and risk mitigation strategies
Chapter 14: Actionable conclusions and strategic recommendations.

Why This Report
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:

Allocate capital strategically to high growth regions (Chapters 6-10) and margin rich segments (Chapter 5).

Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.

Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).

Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).

Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

ページTOPに戻る


Table of Contents

1 Study Coverage
1.1 Introduction to Cattle and Sheep Vaccine: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Cattle and Sheep Vaccine Market Size by Type, 2021 vs 2025 vs 2032
1.2.2 Live Attenuated Vaccine
1.2.3 Inactivated Vaccine
1.2.4 Others
1.3 Market Segmentation by Preventing Disease
1.3.1 Global Cattle and Sheep Vaccine Market Size by Preventing Disease, 2021 vs 2025 vs 2032
1.3.2 Foot-and-Mouth Disease Vaccines
1.3.3 Bovine Respiratory Disease Vaccines
1.3.4 Clostridial Vaccines
1.3.5 Others
1.4 Market Segmentation by Antigen Combination
1.4.1 Global Cattle and Sheep Vaccine Market Size by Antigen Combination, 2021 vs 2025 vs 2032
1.4.2 Monovalent Live Vaccines
1.4.3 Bivalent Live Vaccines
1.4.4 Multivalent Live Vaccines
1.5 Market Segmentation by Application
1.5.1 Global Cattle and Sheep Vaccine Market Size by Application, 2021 vs 2025 vs 2032
1.5.2 Cattle Farming
1.5.3 Sheep Farming
1.5.4 Others
1.6 Assumptions and Limitations
1.7 Study Objectives
1.8 Years Considered

2 Executive Summary
2.1 Global Cattle and Sheep Vaccine Revenue Estimates and Forecasts (2021-2032)
2.2 Global Cattle and Sheep Vaccine Revenue by Region
2.2.1 Revenue Comparison: 2021 vs 2025 vs 2032
2.2.2 Historical and Forecasted Revenue by Region (2021-2032)
2.2.3 Global Revenue-Based Market Share by Region (2021-2032)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends

3 Competitive Landscape
3.1 Global Cattle and Sheep Vaccine Players’ Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2021-2026)
3.1.2 Global Key Players’ Revenue Ranking (2024 vs 2025)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Players (2021 vs 2025)
3.2 Global Cattle and Sheep Vaccine Companies Headquarters and Service Footprint
3.3 Key Player Market Share by Product Type
3.3.1 Live Attenuated Vaccine: Market Share by Key Players
3.3.2 Inactivated Vaccine: Market Share by Key Players
3.3.3 Others: Market Share by Key Players
3.4 Global Cattle and Sheep Vaccine Market Concentration and Dynamics
3.4.1 Global Market Concentration
3.4.2 Market Entry and Exit Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment

4 Product Segmentation
4.1 Global Cattle and Sheep Vaccine Market by Type
4.1.1 Global Revenue by Type (2021-2032)
4.1.2 Global Revenue-Based Market Share by Type (2021-2032)
4.2 Global Cattle and Sheep Vaccine Market by Preventing Disease
4.2.1 Global Revenue by Preventing Disease (2021-2032)
4.2.2 Global Revenue-Based Market Share by Preventing Disease (2021-2032)
4.3 Global Cattle and Sheep Vaccine Market by Antigen Combination
4.3.1 Global Revenue by Antigen Combination (2021-2032)
4.3.2 Global Revenue-Based Market Share by Antigen Combination (2021-2032)
4.4 Key Product Attributes and Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats

5 Downstream Applications and Customers
5.1 Global Cattle and Sheep Vaccine Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2021-2032)
5.1.2 Revenue-Based Market Share by Application (2021-2032)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application

6 North America
6.1 North America Market Size (2021-2032)
6.2 North America Key Players’ Revenue in 2025
6.3 North America Cattle and Sheep Vaccine Market Size by Application (2021-2032)
6.4 North America Growth Accelerators and Market Barriers
6.5 North America Cattle and Sheep Vaccine Market Size by Country
6.5.1 North America Revenue Trends by Country
6.5.2 US
6.5.3 Canada
6.5.4 Mexico

7 Europe
7.1 Europe Market Size (2021-2032)
7.2 Europe Key Players’ Revenue in 2025
7.3 Europe Cattle and Sheep Vaccine Market Size by Application (2021-2032)
7.4 Europe Growth Accelerators and Market Barriers
7.5 Europe Cattle and Sheep Vaccine Market Size by Country
7.5.1 Europe Revenue Trends by Country
7.5.2 Germany
7.5.3 France
7.5.4 U.K.
7.5.5 Italy
7.5.6 Russia

8 Asia-Pacific
8.1 Asia-Pacific Market Size (2021-2032)
8.2 Asia-Pacific Key Players’ Revenue in 2025
8.3 Asia-Pacific Cattle and Sheep Vaccine Market Size by Application (2021-2032)
8.4 Asia-Pacific Growth Accelerators and Market Barriers
8.5 Asia-Pacific Cattle and Sheep Vaccine Market Size by Region
8.5.1 Asia-Pacific Revenue Trends by Region
8.6 China
8.7 Japan
8.8 South Korea
8.9 Australia
8.10 India
8.11 Southeast Asia
8.11.1 Indonesia
8.11.2 Vietnam
8.11.3 Malaysia
8.11.4 Philippines
8.11.5 Singapore

9 Central and South America
9.1 Central and South America Market Size (2021-2032)
9.2 Central and South America Key Players’ Revenue in 2025
9.3 Central and South America Cattle and Sheep Vaccine Market Size by Application (2021-2032)
9.4 Central and South America Investment Opportunities and Key Challenges
9.5 Central and South America Cattle and Sheep Vaccine Market Size by Country
9.5.1 Central and South America Revenue Trends by Country (2021 vs 2025 vs 2032)
9.5.2 Brazil
9.5.3 Argentina

10 Middle East and Africa
10.1 Middle East and Africa Market Size (2021-2032)
10.2 Middle East and Africa Key Players’ Revenue in 2025
10.3 Middle East and Africa Cattle and Sheep Vaccine Market Size by Application (2021-2032)
10.4 Middle East and Africa Investment Opportunities and Key Challenges
10.5 Middle East and Africa Cattle and Sheep Vaccine Market Size by Country
10.5.1 Middle East and Africa Revenue Trends by Country (2021 vs 2025 vs 2032)
10.5.2 GCC Countries
10.5.3 Israel
10.5.4 Egypt
10.5.5 South Africa

11 Corporate Profile
11.1 MSD Animal Health(Merck)
11.1.1 MSD Animal Health(Merck) Corporation Information
11.1.2 MSD Animal Health(Merck) Business Overview
11.1.3 MSD Animal Health(Merck) Cattle and Sheep Vaccine Product Features and Attributes
11.1.4 MSD Animal Health(Merck) Cattle and Sheep Vaccine Revenue and Gross Margin (2021-2026)
11.1.5 MSD Animal Health(Merck) Cattle and Sheep Vaccine Revenue by Product in 2025
11.1.6 MSD Animal Health(Merck) Cattle and Sheep Vaccine Revenue by Application in 2025
11.1.7 MSD Animal Health(Merck) Cattle and Sheep Vaccine Revenue by Geographic Area in 2025
11.1.8 MSD Animal Health(Merck) Cattle and Sheep Vaccine SWOT Analysis
11.1.9 MSD Animal Health(Merck) Recent Developments
11.2 Zoetis
11.2.1 Zoetis Corporation Information
11.2.2 Zoetis Business Overview
11.2.3 Zoetis Cattle and Sheep Vaccine Product Features and Attributes
11.2.4 Zoetis Cattle and Sheep Vaccine Revenue and Gross Margin (2021-2026)
11.2.5 Zoetis Cattle and Sheep Vaccine Revenue by Product in 2025
11.2.6 Zoetis Cattle and Sheep Vaccine Revenue by Application in 2025
11.2.7 Zoetis Cattle and Sheep Vaccine Revenue by Geographic Area in 2025
11.2.8 Zoetis Cattle and Sheep Vaccine SWOT Analysis
11.2.9 Zoetis Recent Developments
11.3 Boehringer Ingelheim
11.3.1 Boehringer Ingelheim Corporation Information
11.3.2 Boehringer Ingelheim Business Overview
11.3.3 Boehringer Ingelheim Cattle and Sheep Vaccine Product Features and Attributes
11.3.4 Boehringer Ingelheim Cattle and Sheep Vaccine Revenue and Gross Margin (2021-2026)
11.3.5 Boehringer Ingelheim Cattle and Sheep Vaccine Revenue by Product in 2025
11.3.6 Boehringer Ingelheim Cattle and Sheep Vaccine Revenue by Application in 2025
11.3.7 Boehringer Ingelheim Cattle and Sheep Vaccine Revenue by Geographic Area in 2025
11.3.8 Boehringer Ingelheim Cattle and Sheep Vaccine SWOT Analysis
11.3.9 Boehringer Ingelheim Recent Developments
11.4 Ceva Santé Animale
11.4.1 Ceva Santé Animale Corporation Information
11.4.2 Ceva Santé Animale Business Overview
11.4.3 Ceva Santé Animale Cattle and Sheep Vaccine Product Features and Attributes
11.4.4 Ceva Santé Animale Cattle and Sheep Vaccine Revenue and Gross Margin (2021-2026)
11.4.5 Ceva Santé Animale Cattle and Sheep Vaccine Revenue by Product in 2025
11.4.6 Ceva Santé Animale Cattle and Sheep Vaccine Revenue by Application in 2025
11.4.7 Ceva Santé Animale Cattle and Sheep Vaccine Revenue by Geographic Area in 2025
11.4.8 Ceva Santé Animale Cattle and Sheep Vaccine SWOT Analysis
11.4.9 Ceva Santé Animale Recent Developments
11.5 Elanco Animal Health
11.5.1 Elanco Animal Health Corporation Information
11.5.2 Elanco Animal Health Business Overview
11.5.3 Elanco Animal Health Cattle and Sheep Vaccine Product Features and Attributes
11.5.4 Elanco Animal Health Cattle and Sheep Vaccine Revenue and Gross Margin (2021-2026)
11.5.5 Elanco Animal Health Cattle and Sheep Vaccine Revenue by Product in 2025
11.5.6 Elanco Animal Health Cattle and Sheep Vaccine Revenue by Application in 2025
11.5.7 Elanco Animal Health Cattle and Sheep Vaccine Revenue by Geographic Area in 2025
11.5.8 Elanco Animal Health Cattle and Sheep Vaccine SWOT Analysis
11.5.9 Elanco Animal Health Recent Developments
11.6 Indian Immunologicals Limited
11.6.1 Indian Immunologicals Limited Corporation Information
11.6.2 Indian Immunologicals Limited Business Overview
11.6.3 Indian Immunologicals Limited Cattle and Sheep Vaccine Product Features and Attributes
11.6.4 Indian Immunologicals Limited Cattle and Sheep Vaccine Revenue and Gross Margin (2021-2026)
11.6.5 Indian Immunologicals Limited Recent Developments
11.7 Cambridge Technologies
11.7.1 Cambridge Technologies Corporation Information
11.7.2 Cambridge Technologies Business Overview
11.7.3 Cambridge Technologies Cattle and Sheep Vaccine Product Features and Attributes
11.7.4 Cambridge Technologies Cattle and Sheep Vaccine Revenue and Gross Margin (2021-2026)
11.7.5 Cambridge Technologies Recent Developments
11.8 Bioveta
11.8.1 Bioveta Corporation Information
11.8.2 Bioveta Business Overview
11.8.3 Bioveta Cattle and Sheep Vaccine Product Features and Attributes
11.8.4 Bioveta Cattle and Sheep Vaccine Revenue and Gross Margin (2021-2026)
11.8.5 Bioveta Recent Developments
11.9 Virbac
11.9.1 Virbac Corporation Information
11.9.2 Virbac Business Overview
11.9.3 Virbac Cattle and Sheep Vaccine Product Features and Attributes
11.9.4 Virbac Cattle and Sheep Vaccine Revenue and Gross Margin (2021-2026)
11.9.5 Virbac Recent Developments
11.10 CZ Vaccines(Zendal Group)
11.10.1 CZ Vaccines(Zendal Group) Corporation Information
11.10.2 CZ Vaccines(Zendal Group) Business Overview
11.10.3 CZ Vaccines(Zendal Group) Cattle and Sheep Vaccine Product Features and Attributes
11.10.4 CZ Vaccines(Zendal Group) Cattle and Sheep Vaccine Revenue and Gross Margin (2021-2026)
11.10.5 Company Ten Recent Developments
11.11 Vaxxinova
11.11.1 Vaxxinova Corporation Information
11.11.2 Vaxxinova Business Overview
11.11.3 Vaxxinova Cattle and Sheep Vaccine Product Features and Attributes
11.11.4 Vaxxinova Cattle and Sheep Vaccine Revenue and Gross Margin (2021-2026)
11.11.5 Vaxxinova Recent Developments
11.12 Hester Biosciences
11.12.1 Hester Biosciences Corporation Information
11.12.2 Hester Biosciences Business Overview
11.12.3 Hester Biosciences Cattle and Sheep Vaccine Product Features and Attributes
11.12.4 Hester Biosciences Cattle and Sheep Vaccine Revenue and Gross Margin (2021-2026)
11.12.5 Hester Biosciences Recent Developments
11.13 Jinyu Bio-Technology
11.13.1 Jinyu Bio-Technology Corporation Information
11.13.2 Jinyu Bio-Technology Business Overview
11.13.3 Jinyu Bio-Technology Cattle and Sheep Vaccine Product Features and Attributes
11.13.4 Jinyu Bio-Technology Cattle and Sheep Vaccine Revenue and Gross Margin (2021-2026)
11.13.5 Jinyu Bio-Technology Recent Developments
11.14 CAHIC
11.14.1 CAHIC Corporation Information
11.14.2 CAHIC Business Overview
11.14.3 CAHIC Cattle and Sheep Vaccine Product Features and Attributes
11.14.4 CAHIC Cattle and Sheep Vaccine Revenue and Gross Margin (2021-2026)
11.14.5 CAHIC Recent Developments
11.15 TECON Biology
11.15.1 TECON Biology Corporation Information
11.15.2 TECON Biology Business Overview
11.15.3 TECON Biology Cattle and Sheep Vaccine Product Features and Attributes
11.15.4 TECON Biology Cattle and Sheep Vaccine Revenue and Gross Margin (2021-2026)
11.15.5 TECON Biology Recent Developments
11.16 Harbin Pharmaceutical Group
11.16.1 Harbin Pharmaceutical Group Corporation Information
11.16.2 Harbin Pharmaceutical Group Business Overview
11.16.3 Harbin Pharmaceutical Group Cattle and Sheep Vaccine Product Features and Attributes
11.16.4 Harbin Pharmaceutical Group Cattle and Sheep Vaccine Revenue and Gross Margin (2021-2026)
11.16.5 Harbin Pharmaceutical Group Recent Developments
11.17 China Agricultural Vet Biology and Technology Co., LTD
11.17.1 China Agricultural Vet Biology and Technology Co., LTD Corporation Information
11.17.2 China Agricultural Vet Biology and Technology Co., LTD Business Overview
11.17.3 China Agricultural Vet Biology and Technology Co., LTD Cattle and Sheep Vaccine Product Features and Attributes
11.17.4 China Agricultural Vet Biology and Technology Co., LTD Cattle and Sheep Vaccine Revenue and Gross Margin (2021-2026)
11.17.5 China Agricultural Vet Biology and Technology Co., LTD Recent Developments
11.18 HIPRA
11.18.1 HIPRA Corporation Information
11.18.2 HIPRA Business Overview
11.18.3 HIPRA Cattle and Sheep Vaccine Product Features and Attributes
11.18.4 HIPRA Cattle and Sheep Vaccine Revenue and Gross Margin (2021-2026)
11.18.5 HIPRA Recent Developments
11.19 Syva
11.19.1 Syva Corporation Information
11.19.2 Syva Business Overview
11.19.3 Syva Cattle and Sheep Vaccine Product Features and Attributes
11.19.4 Syva Cattle and Sheep Vaccine Revenue and Gross Margin (2021-2026)
11.19.5 Syva Recent Developments
11.20 Pulike
11.20.1 Pulike Corporation Information
11.20.2 Pulike Business Overview
11.20.3 Pulike Cattle and Sheep Vaccine Product Features and Attributes
11.20.4 Pulike Cattle and Sheep Vaccine Revenue and Gross Margin (2021-2026)
11.20.5 Pulike Recent Developments
11.21 Shenlian Biomedical
11.21.1 Shenlian Biomedical Corporation Information
11.21.2 Shenlian Biomedical Business Overview
11.21.3 Shenlian Biomedical Cattle and Sheep Vaccine Product Features and Attributes
11.21.4 Shenlian Biomedical Cattle and Sheep Vaccine Revenue and Gross Margin (2021-2026)
11.21.5 Shenlian Biomedical Recent Developments
11.22 INNER MONGOLIA BIGVETBIOTECH
11.22.1 INNER MONGOLIA BIGVETBIOTECH Corporation Information
11.22.2 INNER MONGOLIA BIGVETBIOTECH Business Overview
11.22.3 INNER MONGOLIA BIGVETBIOTECH Cattle and Sheep Vaccine Product Features and Attributes
11.22.4 INNER MONGOLIA BIGVETBIOTECH Cattle and Sheep Vaccine Revenue and Gross Margin (2021-2026)
11.22.5 INNER MONGOLIA BIGVETBIOTECH Recent Developments
11.23 Sinopharm Animal Health
11.23.1 Sinopharm Animal Health Corporation Information
11.23.2 Sinopharm Animal Health Business Overview
11.23.3 Sinopharm Animal Health Cattle and Sheep Vaccine Product Features and Attributes
11.23.4 Sinopharm Animal Health Cattle and Sheep Vaccine Revenue and Gross Margin (2021-2026)
11.23.5 Sinopharm Animal Health Recent Developments
11.24 HVRI
11.24.1 HVRI Corporation Information
11.24.2 HVRI Business Overview
11.24.3 HVRI Cattle and Sheep Vaccine Product Features and Attributes
11.24.4 HVRI Cattle and Sheep Vaccine Revenue and Gross Margin (2021-2026)
11.24.5 HVRI Recent Developments
11.25 Jilin Zhengye
11.25.1 Jilin Zhengye Corporation Information
11.25.2 Jilin Zhengye Business Overview
11.25.3 Jilin Zhengye Cattle and Sheep Vaccine Product Features and Attributes
11.25.4 Jilin Zhengye Cattle and Sheep Vaccine Revenue and Gross Margin (2021-2026)
11.25.5 Jilin Zhengye Recent Developments

12 Cattle and Sheep Vaccine Value Chain and Ecosystem Analysis
12.1 Cattle and Sheep Vaccine Value Chain (Ecosystem Structure)
12.2 Upstream Analysis
12.2.1 Key Technologies, Platforms and Infrastructure
12.3 Midstream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors

13 Cattle and Sheep Vaccine Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints

14 Key Findings in the Global Cattle and Sheep Vaccine Study

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details

ページTOPに戻る



List of Tables/Graphs

List of Tables
Table 1. Global Cattle and Sheep Vaccine Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Table 2. Global Cattle and Sheep Vaccine Market Size Growth Rate by Preventing Disease, 2021 vs 2025 vs 2032 (US$ Million)
Table 3. Global Cattle and Sheep Vaccine Market Size Growth Rate by Antigen Combination, 2021 vs 2025 vs 2032 (US$ Million)
Table 4. Global Cattle and Sheep Vaccine Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Table 5. Global Cattle and Sheep Vaccine Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 6. Global Cattle and Sheep Vaccine Revenue by Region (US$ Million), 2021-2026
Table 7. Global Cattle and Sheep Vaccine Revenue by Region (US$ Million), 2027-2032
Table 8. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 9. Global Cattle and Sheep Vaccine Revenue by Players (US$ Million), 2021-2026
Table 10. Global Cattle and Sheep Vaccine Revenue-Based Market Share by Players (2021-2026)
Table 11. Global Key Players’Ranking Shift (2024 vs 2025) (Based on Revenue)
Table 12. Global Companies by Tier (Tier 1, Tier 2, and Tier 3), based on Cattle and Sheep Vaccine Revenue, 2025
Table 13. Global Cattle and Sheep Vaccine Average Gross Margin (%) by Player (2021 vs 2025)
Table 14. Global Cattle and Sheep Vaccine Companies Headquarters
Table 15. Global Cattle and Sheep Vaccine Market Concentration Ratio (CR5)
Table 16. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis
Table 17. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 18. Global Cattle and Sheep Vaccine Revenue by Type (US$ Million), 2021-2026
Table 19. Global Cattle and Sheep Vaccine Revenue by Type (US$ Million), 2027-2032
Table 20. Global Cattle and Sheep Vaccine Revenue by Preventing Disease (US$ Million), 2021-2026
Table 21. Global Cattle and Sheep Vaccine Revenue by Preventing Disease (US$ Million), 2027-2032
Table 22. Global Cattle and Sheep Vaccine Revenue by Antigen Combination (US$ Million), 2021-2026
Table 23. Global Cattle and Sheep Vaccine Revenue by Antigen Combination (US$ Million), 2027-2032
Table 24. Key Product Attributes and Differentiation
Table 25. Global Cattle and Sheep Vaccine Revenue by Application (US$ Million), 2021-2026
Table 26. Global Cattle and Sheep Vaccine Revenue by Application (US$ Million), 2027-2032
Table 27. Cattle and Sheep Vaccine High-Growth Sectors Demand CAGR (2026-2032)
Table 28. Top Customers by Region
Table 29. Top Customers by Application
Table 30. North America Cattle and Sheep Vaccine Growth Accelerators and Market Barriers
Table 31. North America Cattle and Sheep Vaccine Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 32. Europe Cattle and Sheep Vaccine Growth Accelerators and Market Barriers
Table 33. Europe Cattle and Sheep Vaccine Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 34. Asia-Pacific Cattle and Sheep Vaccine Growth Accelerators and Market Barriers
Table 35. Asia-Pacific Cattle and Sheep Vaccine Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Central and South America Cattle and Sheep Vaccine Investment Opportunities and Key Challenges
Table 37. Central and South America Cattle and Sheep Vaccine Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 38. Middle East and Africa Cattle and Sheep Vaccine Investment Opportunities and Key Challenges
Table 39. Middle East and Africa Cattle and Sheep Vaccine Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 40. MSD Animal Health(Merck) Corporation Information
Table 41. MSD Animal Health(Merck) Description and Major Businesses
Table 42. MSD Animal Health(Merck) Product Features and Attributes
Table 43. MSD Animal Health(Merck) Revenue (US$ Million) and Gross Margin (2021-2026)
Table 44. MSD Animal Health(Merck) Revenue Proportion by Product in 2025
Table 45. MSD Animal Health(Merck) Revenue Proportion by Application in 2025
Table 46. MSD Animal Health(Merck) Revenue Proportion by Geographic Area in 2025
Table 47. MSD Animal Health(Merck) Cattle and Sheep Vaccine SWOT Analysis
Table 48. MSD Animal Health(Merck) Recent Developments
Table 49. Zoetis Corporation Information
Table 50. Zoetis Description and Major Businesses
Table 51. Zoetis Product Features and Attributes
Table 52. Zoetis Revenue (US$ Million) and Gross Margin (2021-2026)
Table 53. Zoetis Revenue Proportion by Product in 2025
Table 54. Zoetis Revenue Proportion by Application in 2025
Table 55. Zoetis Revenue Proportion by Geographic Area in 2025
Table 56. Zoetis Cattle and Sheep Vaccine SWOT Analysis
Table 57. Zoetis Recent Developments
Table 58. Boehringer Ingelheim Corporation Information
Table 59. Boehringer Ingelheim Description and Major Businesses
Table 60. Boehringer Ingelheim Product Features and Attributes
Table 61. Boehringer Ingelheim Revenue (US$ Million) and Gross Margin (2021-2026)
Table 62. Boehringer Ingelheim Revenue Proportion by Product in 2025
Table 63. Boehringer Ingelheim Revenue Proportion by Application in 2025
Table 64. Boehringer Ingelheim Revenue Proportion by Geographic Area in 2025
Table 65. Boehringer Ingelheim Cattle and Sheep Vaccine SWOT Analysis
Table 66. Boehringer Ingelheim Recent Developments
Table 67. Ceva Santé Animale Corporation Information
Table 68. Ceva Santé Animale Description and Major Businesses
Table 69. Ceva Santé Animale Product Features and Attributes
Table 70. Ceva Santé Animale Revenue (US$ Million) and Gross Margin (2021-2026)
Table 71. Ceva Santé Animale Revenue Proportion by Product in 2025
Table 72. Ceva Santé Animale Revenue Proportion by Application in 2025
Table 73. Ceva Santé Animale Revenue Proportion by Geographic Area in 2025
Table 74. Ceva Santé Animale Cattle and Sheep Vaccine SWOT Analysis
Table 75. Ceva Santé Animale Recent Developments
Table 76. Elanco Animal Health Corporation Information
Table 77. Elanco Animal Health Description and Major Businesses
Table 78. Elanco Animal Health Product Features and Attributes
Table 79. Elanco Animal Health Revenue (US$ Million) and Gross Margin (2021-2026)
Table 80. Elanco Animal Health Revenue Proportion by Product in 2025
Table 81. Elanco Animal Health Revenue Proportion by Application in 2025
Table 82. Elanco Animal Health Revenue Proportion by Geographic Area in 2025
Table 83. Elanco Animal Health Cattle and Sheep Vaccine SWOT Analysis
Table 84. Elanco Animal Health Recent Developments
Table 85. Indian Immunologicals Limited Corporation Information
Table 86. Indian Immunologicals Limited Description and Major Businesses
Table 87. Indian Immunologicals Limited Product Features and Attributes
Table 88. Indian Immunologicals Limited Revenue (US$ Million) and Gross Margin (2021-2026)
Table 89. Indian Immunologicals Limited Recent Developments
Table 90. Cambridge Technologies Corporation Information
Table 91. Cambridge Technologies Description and Major Businesses
Table 92. Cambridge Technologies Product Features and Attributes
Table 93. Cambridge Technologies Revenue (US$ Million) and Gross Margin (2021-2026)
Table 94. Cambridge Technologies Recent Developments
Table 95. Bioveta Corporation Information
Table 96. Bioveta Description and Major Businesses
Table 97. Bioveta Product Features and Attributes
Table 98. Bioveta Revenue (US$ Million) and Gross Margin (2021-2026)
Table 99. Bioveta Recent Developments
Table 100. Virbac Corporation Information
Table 101. Virbac Description and Major Businesses
Table 102. Virbac Product Features and Attributes
Table 103. Virbac Revenue (US$ Million) and Gross Margin (2021-2026)
Table 104. Virbac Recent Developments
Table 105. CZ Vaccines(Zendal Group) Corporation Information
Table 106. CZ Vaccines(Zendal Group) Description and Major Businesses
Table 107. CZ Vaccines(Zendal Group) Product Features and Attributes
Table 108. CZ Vaccines(Zendal Group) Revenue (US$ Million) and Gross Margin (2021-2026)
Table 109. CZ Vaccines(Zendal Group) Recent Developments
Table 110. Vaxxinova Corporation Information
Table 111. Vaxxinova Description and Major Businesses
Table 112. Vaxxinova Product Features and Attributes
Table 113. Vaxxinova Revenue (US$ Million) and Gross Margin (2021-2026)
Table 114. Vaxxinova Recent Developments
Table 115. Hester Biosciences Corporation Information
Table 116. Hester Biosciences Description and Major Businesses
Table 117. Hester Biosciences Product Features and Attributes
Table 118. Hester Biosciences Revenue (US$ Million) and Gross Margin (2021-2026)
Table 119. Hester Biosciences Recent Developments
Table 120. Jinyu Bio-Technology Corporation Information
Table 121. Jinyu Bio-Technology Description and Major Businesses
Table 122. Jinyu Bio-Technology Product Features and Attributes
Table 123. Jinyu Bio-Technology Revenue (US$ Million) and Gross Margin (2021-2026)
Table 124. Jinyu Bio-Technology Recent Developments
Table 125. CAHIC Corporation Information
Table 126. CAHIC Description and Major Businesses
Table 127. CAHIC Product Features and Attributes
Table 128. CAHIC Revenue (US$ Million) and Gross Margin (2021-2026)
Table 129. CAHIC Recent Developments
Table 130. TECON Biology Corporation Information
Table 131. TECON Biology Description and Major Businesses
Table 132. TECON Biology Product Features and Attributes
Table 133. TECON Biology Revenue (US$ Million) and Gross Margin (2021-2026)
Table 134. TECON Biology Recent Developments
Table 135. Harbin Pharmaceutical Group Corporation Information
Table 136. Harbin Pharmaceutical Group Description and Major Businesses
Table 137. Harbin Pharmaceutical Group Product Features and Attributes
Table 138. Harbin Pharmaceutical Group Revenue (US$ Million) and Gross Margin (2021-2026)
Table 139. Harbin Pharmaceutical Group Recent Developments
Table 140. China Agricultural Vet Biology and Technology Co., LTD Corporation Information
Table 141. China Agricultural Vet Biology and Technology Co., LTD Description and Major Businesses
Table 142. China Agricultural Vet Biology and Technology Co., LTD Product Features and Attributes
Table 143. China Agricultural Vet Biology and Technology Co., LTD Revenue (US$ Million) and Gross Margin (2021-2026)
Table 144. China Agricultural Vet Biology and Technology Co., LTD Recent Developments
Table 145. HIPRA Corporation Information
Table 146. HIPRA Description and Major Businesses
Table 147. HIPRA Product Features and Attributes
Table 148. HIPRA Revenue (US$ Million) and Gross Margin (2021-2026)
Table 149. HIPRA Recent Developments
Table 150. Syva Corporation Information
Table 151. Syva Description and Major Businesses
Table 152. Syva Product Features and Attributes
Table 153. Syva Revenue (US$ Million) and Gross Margin (2021-2026)
Table 154. Syva Recent Developments
Table 155. Pulike Corporation Information
Table 156. Pulike Description and Major Businesses
Table 157. Pulike Product Features and Attributes
Table 158. Pulike Revenue (US$ Million) and Gross Margin (2021-2026)
Table 159. Pulike Recent Developments
Table 160. Shenlian Biomedical Corporation Information
Table 161. Shenlian Biomedical Description and Major Businesses
Table 162. Shenlian Biomedical Product Features and Attributes
Table 163. Shenlian Biomedical Revenue (US$ Million) and Gross Margin (2021-2026)
Table 164. Shenlian Biomedical Recent Developments
Table 165. INNER MONGOLIA BIGVETBIOTECH Corporation Information
Table 166. INNER MONGOLIA BIGVETBIOTECH Description and Major Businesses
Table 167. INNER MONGOLIA BIGVETBIOTECH Product Features and Attributes
Table 168. INNER MONGOLIA BIGVETBIOTECH Revenue (US$ Million) and Gross Margin (2021-2026)
Table 169. INNER MONGOLIA BIGVETBIOTECH Recent Developments
Table 170. Sinopharm Animal Health Corporation Information
Table 171. Sinopharm Animal Health Description and Major Businesses
Table 172. Sinopharm Animal Health Product Features and Attributes
Table 173. Sinopharm Animal Health Revenue (US$ Million) and Gross Margin (2021-2026)
Table 174. Sinopharm Animal Health Recent Developments
Table 175. HVRI Corporation Information
Table 176. HVRI Description and Major Businesses
Table 177. HVRI Product Features and Attributes
Table 178. HVRI Revenue (US$ Million) and Gross Margin (2021-2026)
Table 179. HVRI Recent Developments
Table 180. Jilin Zhengye Corporation Information
Table 181. Jilin Zhengye Description and Major Businesses
Table 182. Jilin Zhengye Product Features and Attributes
Table 183. Jilin Zhengye Revenue (US$ Million) and Gross Margin (2021-2026)
Table 184. Jilin Zhengye Recent Developments
Table 185. Technologies, Platforms and Infrastructure
Table 186. Distributors List
Table 187. Market Trends and Market Evolution
Table 188. Market Drivers and Opportunities
Table 189. Market Challenges, Risks, and Restraints
Table 190. Research Programs/Design for This Report
Table 191. Key Data Information from Secondary Sources
Table 192. Key Data Information from Primary Sources

List of Figures
Figure 1. Global Cattle and Sheep Vaccine Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Figure 2. Live Attenuated Vaccine Product Picture
Figure 3. Inactivated Vaccine Product Picture
Figure 4. Others Product Picture
Figure 5. Global Cattle and Sheep Vaccine Market Size Growth Rate by Preventing Disease, 2021 vs 2025 vs 2032 (US$ Million)
Figure 6. Foot-and-Mouth Disease Vaccines Product Picture
Figure 7. Bovine Respiratory Disease Vaccines Product Picture
Figure 8. Clostridial Vaccines Product Picture
Figure 9. Others Product Picture
Figure 10. Global Cattle and Sheep Vaccine Market Size Growth Rate by Antigen Combination, 2021 vs 2025 vs 2032 (US$ Million)
Figure 11. Monovalent Live Vaccines Product Picture
Figure 12. Bivalent Live Vaccines Product Picture
Figure 13. Multivalent Live Vaccines Product Picture
Figure 14. Global Cattle and Sheep Vaccine Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Figure 15. Cattle Farming
Figure 16. Sheep Farming
Figure 17. Others
Figure 18. Cattle and Sheep Vaccine Report Years Considered
Figure 19. Global Cattle and Sheep Vaccine Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 20. Global Cattle and Sheep Vaccine Revenue (US$ Million), 2021-2032
Figure 21. Global Cattle and Sheep Vaccine Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Figure 22. Global Cattle and Sheep Vaccine Revenue-Based Market Share by Region (2021-2032)
Figure 23. Global Cattle and Sheep Vaccine Revenue-Based Market Share Ranking (2025)
Figure 24. Tier Distribution by Revenue Contribution (2021 vs 2025)
Figure 25. Live Attenuated Vaccine Revenue-Based Market Share by Player in 2025
Figure 26. Inactivated Vaccine Revenue-Based Market Share by Player in 2025
Figure 27. Others Revenue-Based Market Share by Player in 2025
Figure 28. Global Cattle and Sheep Vaccine Revenue-Based Market Share by Type (2021-2032)
Figure 29. Global Cattle and Sheep Vaccine Revenue-Based Market Share by Preventing Disease (2021-2032)
Figure 30. Global Cattle and Sheep Vaccine Revenue-Based Market Share by Antigen Combination (2021-2032)
Figure 31. Global Cattle and Sheep Vaccine Revenue-Based Market Share by Application (2021-2032)
Figure 32. North America Cattle and Sheep Vaccine Revenue YoY (US$ Million), 2021-2032
Figure 33. North America Top 5 Players Cattle and Sheep Vaccine Revenue (US$ Million) in 2025
Figure 34. North America Cattle and Sheep Vaccine Revenue (US$ Million) by Application (2021-2032)
Figure 35. US Cattle and Sheep Vaccine Revenue (US$ Million), 2021-2032
Figure 36. Canada Cattle and Sheep Vaccine Revenue (US$ Million), 2021-2032
Figure 37. Mexico Cattle and Sheep Vaccine Revenue (US$ Million), 2021-2032
Figure 38. Europe Cattle and Sheep Vaccine Revenue YoY (US$ Million), 2021-2032
Figure 39. Europe Top 5 Players Cattle and Sheep Vaccine Revenue (US$ Million) in 2025
Figure 40. Europe Cattle and Sheep Vaccine Revenue (US$ Million) by Application (2021-2032)
Figure 41. Germany Cattle and Sheep Vaccine Revenue (US$ Million), 2021-2032
Figure 42. France Cattle and Sheep Vaccine Revenue (US$ Million), 2021-2032
Figure 43. U.K. Cattle and Sheep Vaccine Revenue (US$ Million), 2021-2032
Figure 44. Italy Cattle and Sheep Vaccine Revenue (US$ Million), 2021-2032
Figure 45. Russia Cattle and Sheep Vaccine Revenue (US$ Million), 2021-2032
Figure 46. Asia-Pacific Cattle and Sheep Vaccine Revenue YoY (US$ Million), 2021-2032
Figure 47. Asia-Pacific Top 8 Players Cattle and Sheep Vaccine Revenue (US$ Million) in 2025
Figure 48. Asia-Pacific Cattle and Sheep Vaccine Revenue (US$ Million) by Application (2021-2032)
Figure 49. Indonesia Cattle and Sheep Vaccine Revenue (US$ Million), 2021-2032
Figure 50. Japan Cattle and Sheep Vaccine Revenue (US$ Million), 2021-2032
Figure 51. South Korea Cattle and Sheep Vaccine Revenue (US$ Million), 2021-2032
Figure 52. Australia Cattle and Sheep Vaccine Revenue (US$ Million), 2021-2032
Figure 53. India Cattle and Sheep Vaccine Revenue (US$ Million), 2021-2032
Figure 54. Indonesia Cattle and Sheep Vaccine Revenue (US$ Million), 2021-2032
Figure 55. Vietnam Cattle and Sheep Vaccine Revenue (US$ Million), 2021-2032
Figure 56. Malaysia Cattle and Sheep Vaccine Revenue (US$ Million), 2021-2032
Figure 57. Philippines Cattle and Sheep Vaccine Revenue (US$ Million), 2021-2032
Figure 58. Singapore Cattle and Sheep Vaccine Revenue (US$ Million), 2021-2032
Figure 59. Central and South America Cattle and Sheep Vaccine Revenue YoY (US$ Million), 2021-2032
Figure 60. Central and South America Top 5 Players Cattle and Sheep Vaccine Revenue (US$ Million) in 2025
Figure 61. Central and South America Cattle and Sheep Vaccine Revenue (US$ Million) by Application (2021-2032)
Figure 62. Brazil Cattle and Sheep Vaccine Revenue (US$ Million), 2021-2032
Figure 63. Argentina Cattle and Sheep Vaccine Revenue (US$ Million), 2021-2032
Figure 64. Middle East and Africa Cattle and Sheep Vaccine Revenue YoY (US$ Million), 2021-2032
Figure 65. Middle East and Africa Top 5 Players Cattle and Sheep Vaccine Revenue (US$ Million) in 2025
Figure 66. Middle East and Africa Cattle and Sheep Vaccine Revenue (US$ Million) by Application (2021-2032)
Figure 67. GCC Countries Cattle and Sheep Vaccine Revenue (US$ Million), 2021-2032
Figure 68. Israel Cattle and Sheep Vaccine Revenue (US$ Million), 2021-2032
Figure 69. Egypt Cattle and Sheep Vaccine Revenue (US$ Million), 2021-2032
Figure 70. South Africa Cattle and Sheep Vaccine Revenue (US$ Million), 2021-2032
Figure 71. Cattle and Sheep Vaccine Value Chain Mapping
Figure 72. Channels of Distribution (Direct Vs Distribution)
Figure 73. Bottom-up and Top-down Approaches for This Report
Figure 74. Data Triangulation
Figure 75. Key Executives Interviewed

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同じKEY WORD(vaccine)の最新刊レポート


よくあるご質問


QYResearch社はどのような調査会社ですか?


QYリサーチ(QYResearch)は幅広い市場を対象に調査・レポート出版を行う、中国に本社をおく調査会社です。   QYResearchでは年間数百タイトルの調査レポートを出版しています。... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。


詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

 

2026/11/20 10:25

160.51 円

176.53 円

212.83 円

ページTOPに戻る